New hope for HIV patients with Hard-to-Treat hepatitis c

NCT ID NCT00901524

Completed Disease control Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a more intensive hepatitis C treatment in 58 adults who have both HIV and hepatitis C (genotypes 1 or 4) and had not responded to previous therapy. Participants received higher doses of two drugs, peginterferon alfa-2a and ribavirin, for up to 18 months. The goal was to see if this approach could clear the hepatitis C virus from the body for at least six months after treatment ended.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Peginterferon alfa-2a and ribavirin
What this could lead to: If successful, this could offer a more effective treatment option for people with both HIV and hepatitis C who have not responded to standard therapy.
What could go wrong: This is a small, early-phase study with only 58 participants. The treatment involves strong drugs that can cause side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis hepatitis C virus infection HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS

Contacts and locations

Locations

Hôpital Tenon Service des Maladies Infectieuses

Paris, 75970, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.